A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL.
Single-cell RNA sequencing reveals oncogenic transcriptional programs and immune escape mechanisms in over 2 million cells from CTCL patients, highlighting therapeutic vulnerabilities.
- Why it matters: Understanding the transcriptional and microenvironmental landscape of CTCL is crucial to developing more effective, durable treatments for advanced-stage disease, which currently has limited options.
- What they did: The study compiled the largest single-cell atlas of CTCL, analyzing over 2 million skin and blood cells from 116 patients to identify recurrent oncogenic programs and immune cell interactions.
- The result: Findings pinpoint targetable transcriptional pathways and immune components, such as immune checkpoints, enabling the design of combinatorial therapies that exploit these vulnerabilities to improve patient outcomes.